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Abstract
Vascular bubble formation after decompression contributes to endothelial injuries which form the basis for the
development of decompression sickness (DCS). Nitric oxide (NO) is a powerful vasodilator that contributes to vessel
homeostasis. It has been shown that NO-releasing agent may reduce bubble formation and prevent serious decompression
sickness. The use of sildenafil, a well-known, phosphodiesterase-5 blocker, which act by potentiating the vasodilatory effect
on smooth muscle relaxation, has never been studied in DCS. The purpose of the present study was to evaluate the clinical
effects of sildenafil pre-treatment on DCS in a rat model. 67 rats were subjected to a simulated dive at 90 msw for 45 min
before staged decompression. The experimental group received 10 mg/kg of sildenafil one hour before exposure (n = 35)
while controls were not treated (n = 32). Clinical assessment took place over a period of 30 min after surfacing. At the end,
blood samples were collected for blood cells counts and the level of circulating bubbles in the right cavities was quantified.
There were significantly more manifestations of DCS in the sildenafil group than in the controls (34.3% vs 6.25%,
respectively, p = 0.012). Platelet count was more reduced in treated rats than in controls (221.7% vs 27%, respectively,
p = 0.029), whereas bubble grades did not differ between groups. We concluded that pre-treatment with sildenafil
promotes the onset and severity of neurological DCS. When considering the use of phosphodiesterase-5 blockers in the
context of diving, careful discussion with physician should be recommended.
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Introduction
Scuba (self contained underwater breathing apparatus) diving is
an activity growing in popularity every year. Today the diving
population is becoming older and includes many individuals who
are relatively unfit, taking medication. Scuba diving may result in
the production of bubbles due to the release of inert gas originally
held in solution in the form of a free gas phase from peripheral
tissues during decompression. When bubbles are excessively
generated in blood and tissues, signs and symptoms referred to
as decompression sickness (DCS) may occur [1]. It is generally
accepted that gas bubbles grow from pre-formed gas nuclei
attached to the vessel walls [2] and that venous gas emboli
magnitude is linked to an increased risk of DCS [3,4].
Neurological damage in the spinal cord and brain underlies the
most serious symptoms of DCS [5]. Even after standard treatment
with hyperbaric oxygen, 20–30% of the divers affected by
neurological DCS had incomplete recovery at discharge [6]. It is
acknowledged that vascular bubble formation contribute to
endothelial injury leading to vascular obstruction, microcirculatory
alterations and activation of coagulation cascades, which may
form the basis for the development of DCS [5,7].
It has been shown that endothelial nitric oxide (NO) is a critical
factor in the development of bubble formation and decompression
sickness [8]. NO, which is gas highly soluble in lipids, may cross
biological membranes and diffuse to the subjacent vascular smooth
muscle where it regulates vascular tones by activation of the
enzyme guanylate cyclase. This increases intracellular cyclic
guanosine monophosphate (cGMP) concentrations leading to
vasodilation from relaxation of the smooth muscle cells. NO
may also act on the luminal endothelial surface by inhibiting
platelet aggregation and leukocyte adhesion, scavenging free
radicals and modulating the permeability of endothelial layer
[9,10]. NO, through its multiple properties, could facilitate the
elimination of vascular gaseous nuclei, thereby reducing the
formation of bubbles during decompression. Previous studies have
shown that blockade of NO synthesis with L-NAME dramatically
increases peripheral vascular resistances and bubble formation in
rats with a reduction of survival after decompression [11].
Conversely, prolonged or immediate (30 minutes) administration
of NO-releasing agent (isosorbid mononitrate) before simulated
diving protects animals against bubble formation and death [8,12].
Similar results were obtained on volunteer human divers by
demonstrating that application of short-acting NO donor (0.4 mg
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of nitroglycerine by oral spray) 30 minutes before the dive reduced
the number of venous circulating bubbles [13].
However, the use of phosphodiesterase (PDE)-5 blockers, which
act by potentiating the action of cGMP in vascular smooth muscle
cells, has never been studied in DCS. Sildenafil, sold as ViagraTM,
RevatioTM, and under various other trade names, is a selective and
potent inhibitor of PDE type 5 which specifically degrades cGMP
and is found in platelets, skeletal muscle, and visceral and
pulmonary vascular smooth muscle, as well as in cerebral neurons
and vessels [14,15]. However the highest concentrations are
observed in pulmonary arteries and the corpora cavernosum
[16,17]. For a decade, sildenafil citrate has become one of the top-
selling products in the world-wide market for male impotence
treatment. Inhibition of PDE-5 present in the endothelium of the
corpora cavernosa prolongs the relaxation of the pericavernous
smooth muscle, sustaining its engorgement with blood [18].
Sildenafil is generally well tolerated, with most side effects related
to vasodilation i.e. headache, flushing [19,20]. However, recent
concern and media coverage of temporally related cardiovascular
events, including myocardial infarction, arrhythmias, and death,
reported after the release of sildenafil onto the market raised
questions regarding the safety of sildenafil in patients with
cardiovascular disease [21]. Other serious but rare adverse effects
have been also reported, i.e. life-threatening intracerebral hemor-
rhage in a young adult male [22]. Indeed, sildenafil may act by
redistributing arterial cerebral blood flow, which may result in
some cases to rupture of vessels. PDE-5 inhibitors may also
increase the risk of central nervous system (CNS) oxygen toxicity
by enhancing cerebral blood flow under conditions that can occur
in diving or during hyperbaric oxygen administration [23].
Based on its properties, sildenafil could have a beneficial role on
decompression by reducing bubble formation. On the other hand,
its vascular impact on the central nervous system is not known in
the context of diving and severe decompression. To our
knowledge, there are no reported data on the occurrence of
DCS in divers taking sildenafil. The purpose of the present study
was to evaluate the clinical effects of sildenafil pre-treatment on
DCS in a rat model. To complete this analysis, we also determined
the level of circulating vascular bubbles in the right cavities and
counted blood cells.
Materials and Methods
Study Population
All procedures involving experimental animals were in line with
European Union rules (Directive 86/609) and French law (Decree
87/848). The ethics committee of Institut de Recherche
Biome´dicale des Arme´es approved this study. Our investigator
(NV) is associated to the agreement number 83.6 delivered by the
Health and Safety Directorate of our department, as stated in the
French rules R.214-93, R-214-99 and R.214-102.
Only male Sprague-Dawley rats (Harlan Laboratories, France)
were used in this experiment in order to avoid fluctuations due to
female hormone cycles. Rats were kept at 2261uC in a 12:00/
12:00-h light/dark cycle (lights on at 7:00 a.m.) with food (A03,
UAR) and water ad libidum. Before experiments, rats were housed
in an accredited animal care facility. All procedures involving
experimental animals were in line with European Union rules
(Directive 86/609) and French law (Decree 87/848).
A total of 67 rats were exposed to compressed air to induce
decompression stress and bubble formation. The rats were
randomly divided into two groups and numbered: 35 for the
group treated with sildenafil and 32 for the controls. The
experimental design is detailed in Figure 1. Previous studies
showed that bubble formation and incidence of decompression
sickness were highly dependent upon body weight of the rat
[24,25,26]. Protocols using rats with a body weight above 350 g
produced severe DCS with severe neurological symptoms and
death. Weight was similar in both groups (361615 g for sildenafil
vs 358612 g for controls, p = 0.510). The rats of experimental
group received a single gavage dose of 10 mg/kg of sildenafil
solution (0.5 ml) in the form of ViagraTM (Pfizer) 1 hour before
hyperbaric exposition while the control group received a similar
volume of water (0.5 ml) without sildenafil. The selected dose has
been previously shown to be effective in a rat model of embolic
stroke [27] and time of administration of sildenafil was adjusted
according its onset of action with a peak at 60 minutes.
Hyperbaric Procedure
Batches of 10 freely-moving rats (8–10 per cage) were subjected
to the hyperbaric protocol in a 200-liter tank fitted with three ports
for observation.
Rats underwent the compression procedure at a rate of
100 kPa.min21 to a pressure of 1000 kPa (90 msw), maintained
for 45 min while breathing air. At the end of the exposure period
rats were decompressed down to 200 kPa at a rate of
100 kPa.min21 with a 5-min stop at 200 kPa, a 5-min stop at
160 kPa, and a 10-min stop at 130 kPa. Decompression between
200 kPa and surface was performed at a rate of 10 kPa.min21.
The decompression rate was automatically controlled by a
computer linked to an Analogical/Digital converter (NIUSB-
6211, National Instrument, USA) itself connected to a solenoid
valve (Belino LR24A-SR, Switzerland) and a pressure transmitter
(Pressure Transmitter 8314, Burket Fluid Control System,
Germany). The program used to control decompression rate was
designed on DasyLab (DasyLab National Instrument, USA) by our
engineer.
Compressed air was generated using a diving compressor (Mini
Verticus III, Bauer Comp, Germany) coupled to a 100-liter tank at
300 bars. The oxygen analyzer was based on a MicroFuel
electrochemical cell (G18007 Teledyne Electronic Technologies/
Analytical Instruments, USA).Water vapor and CO2 produced by
the animals were respectively captured with seccagel (relative
humidity: 40–60%) and soda lime (,300 ppm captured by the
soda lime), respectively. Gases were mixed by an electric fan. The
day-night cycle was respected throughout. The temperature inside
the tank was measured using a platinum-resistance temperature
probe (Pt 100, Eurotherm, France). All these variables were
controlled by a dedicated computer.
Behavior and Clinical Observations
At the end of decompression, the rats were transferred to
individual cages and observed during 30 minutes by a dedicated
staff, blinded to treatment. The following symptoms were
considered as manifestations of DCS: labored breathing, paralysis
or moving difficulties (including limping, failure to maintain
balance, sideways gait, falling, difficulty righting after a fall), and
death. The time of onset of these symptoms were also recorded.
Problems with fore or rear limbs were classified as being due to
neurological DCS.
Blood Cells Tests
Blood tests were carried out in an automatic analyzer (ABCvet,
SCIL, France) on samples taken before the dive and then again 30
minutes after surfacing. Red cells, leukocytes and platelets were
counted in 20 ml samples taken from the tip of the tail and diluted
in an equivalent volume of 2 mM EDTA (Sigma, France).
Viagra and DCS
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Bubble Detection
The rats were anesthetized 30 minutes after surfacing by
intraperitoneal injection of a mixture of 10 mg/kg xylazine
(RompumH 2%, Bayer Pharma) and 100 mg/kg ketamine
(ImalgeneH1000, Laboratoire Rhoˆne, France). Bubble detection
was performed using a Micromaxx Sonosite, with a probe of 4–
8 Mhz. Bubbles were identified as bright spots in the right
ventricule with 2D mode. Bubbles were graded according to the
Spencer scale [4] using the pulsed Doppler mode. The observer
was blinded to the group allocation of the rat. At the end of the
experiment, the rats were sacrificed by injecting pentobarbital
(200 mg/kg ip, Sanofi Sante´, France).
Statistical Analyses
For statistical processing, we used Sigmastat 3.0 (SPSS inc.,
Chicago, Illinois). Numerical results were expressed as median and
interquartile range. A contingency table was used for indepen-
dence and association tests, coupled with a Fisher Exact or Chi2
test of significance. Differences between two groups were analysed
by a Mann-Whitney test, whereas matched comparisons within
groups used a Wilcoxon test. A difference was considered as
significant for p-values ,0.05.
Results
Clinical Observations (Figure 2)
The rats expressed mainly neurological symptoms of varying
intensity including locomotor impairment i.e. paraplegia or
paraparesis, often followed by the death of the animal. All cases
of neurological symptoms occurred within 5 min after surfacing.
In a few cases, respiratory symptoms were also noted (2 cases in
each group). There was significantly more neurological symptoms
of DCS in the sildenafil group compared with the controls (34.3%
vs 6.25%, respectively, p = 0.012). Death, generally preceded by
paraplegia, occurred more frequently in the sildenafil group, with
a significant difference (34.3% vs 9.4%, respectively, p = 0.032).
Additional analysis found that time to death (9613.5 min for
sildenafil vs 166.5 min for controls, p = 0.515) and time to onset
of DCS symptoms were not significantly different between groups
(median of 1 min in each group, p = 0.882).
Bubble Detection (Figure 2)
Bubbles were observed in 72.7% of animals treated with
sildenafil and in 56.6% for controls, but this difference was not
significant (p = 0.371). Moreover, no differences in bubble grades
Figure 1. Flow chart describing the experimental design.
doi:10.1371/journal.pone.0060639.g001
Figure 2. Percents of dead rats and animals presenting
neurological symptoms of decompression sickness within
30 min after surfacing. Percents of rats with high bubble grades
(Spencer grades 3 and 4) during precordial bubble detection are also
represented. Histogram in dark grey represents the group treated with
sildenafil and light grey represents the controls. * denotes p,0.05
between groups.
doi:10.1371/journal.pone.0060639.g002
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were observed between groups (p = 0.266), with a median grade of
263 for the sildenafil group and 163 for controls. High bubble
grades i.e. Spencer grades 3 and 4 were found in 36% and 27% of
treated animals and controls, respectively.
Blood Cells (Figure 3)
Platelet counts. Following the dive, the platelet count was
reduced by 221.7625.4% from baseline in the sildenafil group
while the decrease was only 27613.8% in the controls. This
difference between groups was significant (p = 0.029).
Leukocyte counts. Following the dive, the leukocyte count
was decreased from baseline by 226653% in the sildenafil group
and by 220637% in the controls, with no statistical differences
between groups (p = 0.739).
Red cells. Following the dive, the red cell went down by
26.7610.3% from baseline in the sildenafil group and by
27.167.5% in the control group, with no statistical differences
between groups (p = 0.431).
Discussion
The aim of the present study was to investigate the effects of
sildenafil in a clinically relevant model of DCS that produces
motor impairment suggestive of neurological DCS [24,25,26]. The
main finding in this study is that rats treated with sildenafil had
greater DCS incidence, as assessed both by clinical observations
and biomarkers such as platelets consumption.
We found that platelet count was more reduced in treated rats
than in controls. This result reflects the severity of clinical DCS in
the group treated with sildenafil. Indeed animal experiments
strongly suggest a role for the involvement of blood components in
DCS [5,28]. Previous animal studies reported that platelet count
falls following decompression and can be considered to be a
relevant index for evaluating decompression stress [26,28]. The
drop in platelet count is usually attributed to clotting activity
following exposure of the collagen under bubble-damaged
endothelial cells in the blood vessels [7,29], or direct interaction
between bubbles and platelets [30,31]. Concerning leukocytes and
red cells, we did not find significant differences between groups.
Experimental observations in DCS suggest that damage to the
vascular endothelium by gas bubbles may provoke an inflamma-
tory and immune response resulting in leukocyte activation. The
fall in leukocyte count after DCS is usually attributed to diapedesis
[32]. Several authors have observed phenomena of blood sludging
and red-cell fragmentation/deformation following rapid decom-
pression in animal models. The formation of red-cell aggregates
appears to be associated with flow stasis [28]. However the use of
leukocyte and red cell counts do not seem as powerful as platelet
count in DCS evaluation [28].
We believe that the promoting effect of sildenafil on the
occurrence of DCS may be related to vasodilation in the CNS with
increased cerebral blood flow [23]. This effect may contribute to
significantly increasing the load of inert gas during the hyperbaric
exposure and thereby generate bubbling and severe DCS in
neurological tissue. The elevation of cerebral blood flow can also
be deleterious in specific circumstances. Demchenko et al. [23]
demonstrated that conscious rats treated with sildenafil before an
exposure to hyperbaric oxygen were more susceptible to CNS
oxygen toxicity, as demonstrated by significantly shortened
convulsive latency. This result demonstrated that sildenafil opposes
the protective vasoconstriction that is the initial response to
hyperbaric hyperoxia, by hastening onset of CNS oxygen toxicity.
Since the neurological signs that we observed were primarily
motor impairment with no case of convulsions, it is unlikely that
relative hyperoxia (equivalent exposure to 90 msw in air
atmosphere, 200 kPa O2) may have played a role in the onset of
neurological symptoms in the present study. However it is possible
that increased oxidative stress may have contributed to promote
the onset of neurological DCS. Indeed, increased cerebral blood
flow leading to increased oxidative stress may produce peroxyni-
trites, and several studies have reported such toxicity after
ischemia and reperfusion [33] or traumatic brain injury [34].
However, in other circumstances the elevation of cerebral blood
flow can be beneficial. Indeed, previous studies demonstrated that
treatment of experimental stroke with sildenafil, initiated at 24 h
after onset of ischemic stroke was associated with improvement of
functional recovery compared with saline-treated rats [27,35].
Cerebral blood flow values of the ischemic tissue along the
ischemic lesion boundary area measured by MRI were signifi-
cantly elevated in sildenafil treated rats compared with control rats
[35]. These aforementioned experimental studies suggest that
sildenafil could be useful as an adjuvant treatment of ischemic
neurological DCS that have not recovered after initial treatment
with hyperbaric oxygen.
Previous experimental studies have shown that NO donors i.e.
nitrates are able to remove vascular bubbles both in rats and man
[8,12,13], probably by eliminating gas nuclei before hyperbaric
exposure. However, we found in our study, that sildenafil was not
able to reduce bubble formation. Thus, NO donors must involve
properties and mechanisms different from those encountered with
sildenafil. This suggests that the presence of gas nuclei attached to
the vessel wall is not directly influenced by the vasodilator effect
related to the relaxation of the smooth muscle induced by the
increase of cGMP. Indeed, sildenafil prevents the degradation of
cGMP by inhibiting PDE-5, and therefore acts on cGMP by a
mechanism different from the NO pathway. Apart from its
vasodilator effect related to vascular smooth muscle relaxation,
NO also diffuses to the luminal surface of the endothelium, where
it exerts a number of important physiological effects, including
scavenging of superoxide radicals, inhibition of platelet adherence
and aggregation, modulation of endothelial layer permeability and
attenuation of leukocyte function. We believe that these specific
effects of NO, which are not reported with sildenafil, could be
involved in the reduction of the number of gas nuclei adhering to
the surface.
Our results do not render obsolete the previous works on the
prevention of decompression sickness by preconditioning methods
such as exercise or sauna that stimulate the production of
Figure 3. Percents of blood cells consumption after decom-
pression from the baseline in dark grey for the group of rats
treated with sildenafil and light grey for the controls. * denotes
p,0.05 between groups.
doi:10.1371/journal.pone.0060639.g003
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endogenous NO and reduce bubble formation [36,37]. Exogenous
NO pre-treatment from low doses of nitrates may also reduce
vascular bubbles both in rats and man [8,12,13]. All these
beneficial effects on bubble formation and DCS could be
associated with antitadhesive and antithrombotic properties of
NO and not to its vasodilator effect.
The results of our pilot study suggest that inhibitors of PDE-5
such as sildenafil are potentially dangerous pre-treatments, which
can promote the occurrence of DCS. This promoting effect could
be related to vasodilation with increased cerebral blood flow.
Further studies, including the assessment of oxidative stress
markers with production of peroxynitrites in CNS may be relevant
to elucidate the underlying mechanisms of sildenafil in DCS.
In conclusion, since pre-treatment with sildenafil promotes the
onset and severity of neurological decompression sickness, it is
important to inform the community of divers from potential risks
associated with inhibitors of PDE-5 treatment for diving activities;
when considering their usage in the context of diving, careful
discussion with a physician should be recommended.
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